Shareholder AnnouncementDear Shareholder,I am pleased to announce that we have entered into an Agreement with MSD (or Merck Sharp & Dohme, tradename of Merck & Co., USA), to evaluate our lead anticancer pharmaceutical tigilanol tiglate in combination with MSD’s Keytruda® (pembrolizumab) in patients with melanoma. The Agreement encompasses a clinical trial collaboration to investigate the safety and preliminary efficacy of tigilanol tiglate when administered in combination with Keytruda® in a Phase Ib/IIa open label, dose escalation study. What we hope to see through this program, is that when combined, tigilanol tiglate and Keytruda® will be safe and produce an additive anti-tumour immune response with an improved outcome for patients. This clinical collaboration is a significant milestone for QBiotics, and we are delighted to work with such a high calibre company as MSD on this study. Melanoma is the second human application QBiotics is pursuing for tigilanol tiglate following on from our Phase Ib/IIa clinical trial in patients with Head and Neck Squamous Cell Carcinoma which commenced in December 2019.
- Forums
- ASX - General
- cure for cancer...you can invest
Shareholder AnnouncementDear Shareholder,I am pleased to...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online